Erratum: Mechanisms underlying vascular effect of chronic resveratrol in streptozotocin-diabetic rats (Phytotherapy Research (2010) 24, Supplement 2 DOI: 10.1002/ptr.3032);Mechanisms underlying vascular effect of chronic resveratrol in streptozotocin-diabetic rats

Phytotherapy Research

Volumn 24, Issue SUPPL. 2, 2010, Pages

  Roghani, Mehrdad ^a   Baluchnejadmojarad, Tourandokht ^b  

^a SHAHED UNIVERSITY   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aorta; Diabetes mellitus; Resveratrol

Indexed keywords

ACETYLCHOLINE; INDOMETACIN; MALONALDEHYDE; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; POTASSIUM CHLORIDE; RESVERATROL; SUPEROXIDE DISMUTASE; ANTIDIABETIC AGENT; STILBENE DERIVATIVE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIVER; LONG TERM CARE; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; VASCULAR SMOOTH MUSCLE; WISTAR RAT;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; AORTA; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; STILBENES; SUPEROXIDE DISMUTASE; VASOCONSTRICTOR AGENTS;

EID: 77953905452     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3253     Document Type: Erratum

References (20)

1. Abebe W, Harris KH, Macleod KM. 1990. Enhanced contractile responses of arteries from diabetic rats to a11-adrenoceptor stimulation in the absence and presence of extracellular calcium. J Cardiovasc Pharmacol 16: 239-248.
2. Bradamante S, Barenghi L, Villa A. 2004. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22: 169-188.
3. Chen L, Liang B, Froese DE, Liu S, Wong JT, Tran K, Hatch GM., Mymin D, Kroeger EA, Man RY, Choy PC. 1997. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res 38: 546-553.
4. Chen H, Carison EC, Pellet L, Moritz JT, Epstein PN. 2001. Overexpression of metallothionein in pancreatic β-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 50: 2040-2046.
5. De Vriese AS, Verbeuren TJ, Van de Voode J, Lameire NH, Vanhoutte PM. 2000. Endothelial dysfunction in diabetes. Br J Pharmacol 130: 963-974.
6. Fremont L. 2000. Biological effects of resveratrol. Life Sci 66: 663-673.
7. Huang THW, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, Li Y. 2005. Anti-diabetic action of Punica granatum flower extract: activation of PPAR-c and identification of an active component. Toxicol Appl Pharmacol 207: 160-169.
8. Ji H, Jiang JY, Xu Z, Kroeger EA, Lee SS, Liu H, Shen H, Zhang M, Minuk GY, Choy PC, Gong Y. 2003. Change in lipid profile and impairment of endothelium-dependent relaxation of blood vessels in rats after bile duct ligation. Life Sci 73: 1253-1263.
9. Kamata K, Miyata N, Kasuya Y. 1989. Impairment of endothelium-dependent relaxation and changes on levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 97: 614-618.
10. Mitra SK, Gopumadhavan S, Muralidhar TS, Anturlikar SD, Sujatha MB. 1995. Effect of D-400, a herbomineral preparation on lipid profile, glycated hemoglobin and glucose tolerance in STZ induced diabetes in rats. Indian J Exp Biol 33: 798-800.
11. Nabel EG. 2003. Cardiovascular disease. New Engl J Med 349: 60-72.
12. Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, Kim SS, Ha J. 2007. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 39: 222-229.
13. Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menan VP, Bagchi D, Maulik N. 2008. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/AKT/eNOS signaling pathway in diabetic myocardium. J Cell Mol Med (in press).
14. Pervaiz S. 2003. Resveratrol: from grapevines to mammalian biology. FASEB J 17: 1975-1985.
15. Rodrigo R, Bosco C. 2006. Oxidative stress and protective effects of polyphenols: comparative studies in human and rodent kidney, a review. Comp Biochem Physiol C 142: 317-327.
16. Senses V, Ozyazgan S, Ince E, Tuncdemir M, Kaya F, Ozturk M, Sultuybek G, Akkan AG. 2001. Effect of 5-aminoimidazole-4-carboxamide riboside (AICA-r) on isolated thoracic aorta responses in streptozotocin-diabetic rats. J Basic Clin Physiol Pharmacol 12: 227-248. (Pubitemid 33143992)
17. Silan C. 2008. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull 31: 897-902. (Pubitemid 351731986)
18. Su HC, Hung LM, Chen JK. 2006. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocininduced diabetic rats. Am J Physiol Endocrinol Metab 290: E1339-E1346.
19. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U. 2002. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106: 1652-1658.
20. Wolffe SP, Jiang ZY, Hunt JV. 1991. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 10: 339-352.